SION earnings analysis
What we found in SION's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Sionna Therapeutics reported a Q1 2026 net loss of $26.8 million, significantly up from a loss of $16.5 million in Q1 2025. Operating expenses surged to $29.6 million, driven by increased research and development (R&D) and general administrative (G&A) expenses. The company maintains a healthy cash position of $289.9 million, expected to fund operations into 2028, but continues to face substantial cash burn as it progresses its cystic fibrosis product candidates through clinical trials.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Increased R&D Investments
- R&D expenses rose to $18.96 million in Q1 2026, up from $13.67 million in Q1 2025, reflecting heightened clinical activity.
- Significant Cash Reserves
- As of March 31, 2026, cash, cash equivalents, and marketable securities stand at $289.9 million, sufficient to fund operations into 2028.
- Rising Operating Expenses
- Total operating expenses totaled $29.6 million for Q1 2026, up from $19.7 million in Q1 2025, driven by G&A costs.
- Strong Pipeline Development
- Two product candidates, SION-719 and SION-451, are advancing through clinical trials, which management cites as key growth drivers.
- Increased Net Loss
- Net loss for Q1 2026 was $26.8 million, compared to $16.5 million for Q1 2025, marking a growing financial strain.
- Commitment to Clinical Trials
- Completion of enrollment for the Phase 2a trial for SION-719 and a Phase 1 trial for SION-451 demonstrates ongoing clinical commitment.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Rising Operating Costs
- Total operating expenses increased by $9.94 million to $29.6 million for Q1 2026 compared to Q1 2025.
- Dependence on Clinical Trials
- No revenue generated; the company is entirely reliant on the success of ongoing clinical trials to drive future revenue.
- Competing Products
- Significant competition in the cystic fibrosis treatment space, especially from established players like Vertex Pharmaceuticals.
What they said about what is next.
No numeric revenue or EPS guidance provided; outlook is focused on the pipeline and funding.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 2, 2026
- Sionna is a clinical‑stage biotech focused on directly stabilizing CFTR’s NBD1 to treat cystic fibrosis, advancing multiple small‑molecule NBD1 stabilizers (SION‑719 and SION‑451) and complementary modulators toward…
- 10-Q · May 12, 2025
- Sionna reported a net loss of $16.5M (-$0.62 per share) for the quarter ended March 31, 2025, compared with a net loss of $11.8M (-$3.84) in Q1 2024; operating expenses rose to $19.7M from $13.1M driven by higher R&D…
- 10-K · March 20, 2025
- Sionna is a clinical-stage biopharmaceutical company focused on NBD1-targeted CFTR stabilizers and complementary modulators to address remaining unmet need in cystic fibrosis. The company has advanced two NBD1…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SION makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever